ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
28.25
+0.03 (0.11%)
Jul 21, 2026, 1:11 PM EDT - Market open
ArriVent BioPharma Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, ArriVent BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $43.64. The average 1-year stock price forecast is 54.48% higher than the current stock price, while the lowest is $34 (+20.35%) and the highest is $50 (+76.99%).
Price Target: $43.64 (+54.48%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 12 | 12 | 12 | 12 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $42 | Buy | Maintains | $42 | +48.67% | Jul 15, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $42 | Buy | Maintains | $42 | +48.67% | Jul 14, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $45 | Buy | Maintains | $45 | +59.29% | Jul 6, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $32 | Buy | Reiterates | $32 | +12.35% | Jun 22, 2026 |
| Citi | Citi | Buy Maintains $43 | Buy | Maintains | $43 | +52.21% | Jun 4, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
42.75M
EPS This Year
-4.02
from -4.32
EPS Next Year
-3.50
from -4.02
EPS and Forward PE are based on non-GAAP adjusted numbers.